tirzepatide 60 mg Body Pharm Pen Tirzepatide Pen 60 mg Support

Seek immediate emergency care (call 911 or go to the emergency department) for: Sudden severe chest pain or pressure Difficulty breathing or shortness of breath at rest Coughing up blood Sudden weakness, numbness, difficulty speaking, vision changes, or severe headache (stroke symptoms) Severe leg pain with swelling and skin color changes Fainting or loss of consciousness Sudden severe abdominal pain (which could indicate pancreatitis, a known rare semaglutide risk) Signs of severe allergic reaction (rash, itching, swelling of face/throat, difficulty breathing) Contact your healthcare provider within 24 hours for: New or worsening leg swelling, especially if unilateral Persistent calf pain or tenderness Unexplained shortness of breath with exertion New onset of rapid heart rate Persistent severe nausea or vomiting preventing adequate hydration Sudden vision changes (potential retinopathy complication) Right upper quadrant pain, fever, or yellowing of skin/eyes (potential gallbladder disease) Markedly decreased urination (potential kidney issue) Positive pregnancy test (semaglutide should be discontinued) Schedule a routine appointment to discuss: Planned surgeries or procedures New medications or supplements Significant changes in activity level or mobility Pregnancy planning (semaglutide should be discontinued at least 2 months before planned conception) Concerns about medication side effects Difficulty with injection technique or medication adherence Patients should generally not discontinue semaglutide abruptly without medical guidance, as this may affect glycemic control in those with diabetes

Ment Retard Dev Disabil Res Rev

While seizures are not an expected complication of GLP-1 receptor agonist therapy, any seizure-like event requires urgent assessment regardless of medication use

Hao X, Zhang T, Yang Y, Feng H, Wang Y, Song Y, Su Y, Guo S